22426-86-4

Basic information

• Product Name: N-(benzyloxy)-2-phenylacetamide
• Synonyms: N-(benzyloxy)-2-phenylacetamide
• CAS NO: 22426-86-4
• Molecular Weight: 241.29
• Mol File: 22426-86-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(benzyloxy)-2-phenylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(benzyloxy)-2-phenylacetamide(22426-86-4)
• EPA Substance Registry System: N-(benzyloxy)-2-phenylacetamide(22426-86-4)

Safety Data

• Hazardous Substances Data: 22426-86-4(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 622-33-3 N-benzyloxyamine 
• 103-80-0 phenylacetyl chloride 
• 101-97-3 Ethyl 2-phenylethanoate 
• 103-82-2 phenylacetic acid 
• 5330-97-2 N-hydroxy-2-phenylacetamide 

Downstream Products

• 103-30-0 (E)-1,2-diphenyl-ethene 
• 7500-45-0 N-benzylphenylacetamide 
• 100-52-7 benzaldehyde 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 
• 100-51-6 benzyl alcohol 
• 22426-99-9 N-Acetyl-O-benzyl-N-phenylacetyl-hydroxylamin 
• 5330-97-2 N-hydroxy-2-phenylacetamide 
• 1402345-78-1 N-(benzyloxy)-N-(2-fluorophenyl)-2-phenylacetamide 
• 1402345-69-0 N-(benzyloxy)-2-phenyl-N-(4-tolyl)acetamide 
• 1402345-82-7 N-(benzyloxy)-N-(2-methoxyphenyl)-2-phenylacetamide 
• 1402345-41-8 N-(benzyloxy)-N,2-diphenylacetamide 
• 77130-75-7 acide N-acetyl phenyl-2 acetohydroxamique 
• 20989-17-7 Phenylglycinol 
• 63820-42-8 Methyl-(E)-O-benzyl-phenylacetohydroximat 

Relevant articles and documents

Synthesis of O-benzyl hydroxamates employing the sulfonate esters of N-hydroxybenzotriazole

The direct conversion of various carboxylic acids, that include sterically hindered amino acids and di-peptides, to O-benzyl hydroxamates is demonstrated using sulfonate esters of benzotriazoles under ambient and milder conditions without significant race

Coordination chemistry based approach to lipophilic inhibitors of 1-deoxy-D-xylulose-5-phosphate reductoisomerase

1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) in the non-mevalonate pathway found in most bacteria is a validated anti-infective drug target. Fosmidomycin, a potent DXR inhibitor, is active against Gram-negative bacteria. A coordination chemistry and structure based approach was used to discover a novel, lipophilic DXR inhibitor with an IC50 of 1.4 μM. It exhibited a broad spectrum of activity against Gram-negative and -positive bacteria with minimal inhibition concentrations of 20-100 μM (or 3.7-19 μg/mL).